KHẢO SÁT BAN ĐẦU NỒNG ĐỘ HBcrAg Ở BỆNH NHÂN VIÊM GAN B MẠN TÍNH ĐANG ĐIỀU TRỊ THUỐC KHÁNG VI RÚT nucleos(t)ide

Abstract

Background: Hepatitis B virus (HBV) infection is a global public health problem due to its high prevalence and dangerous complications. The treatment in patients with chronic hepatitis B virus will help suppress the virus, reduce the risk of cirrhosis, hepatocellular cancer as well as mortality rate. However, the treatment of HBV requires a long time and continuous monitoring and evaluation of viral biomarkers such as HBV DNA, HBeAg, HBsAg. The new biomarker HBcrAg in recent studies has shown superiority in treatment monitoring and discontinuation assessment in patients with chronic hepatitis B.

Objectives: to describe HBcrAg level in chronic hepatitis B patients receiving antiviral therapy with nucleotide/nucleoside analogues with HBsAg level below 80UI/ml. Time and location: from January to June 2021 at the Outpatient Department of Giai Phong, National Hospital for Tropical Diseases. Method: a cross-sectional study.

Results and conclusions: 92 patients with chronic hepatitis B receiving nucleos(t)ide analogues for 3-5 years were eligible to enrol in the study with 65.2% of females and an average age of 45.1 years. ± 14.9 (age). Patients with HBeAg (+) accounted for 3.3%. Nearly ¾ patients had a very low HBsAg level of < 20 UI/ml, of which 25.2% were HBsAg negative. In contrast, 3/4 patients had the HBcrAg levels > 3 log UI/ml despite uncountable HBV DNA levels.